<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(11)</volume><submitter>Dolat M</submitter><pubmed_abstract>In order to limit 5-fluorouracil (5-FU) toxicity, some health agencies recommend evaluating dihydropyrimidine dehydrogenase (DPD) deficiency before any 5-FU treatment introduction. In our study, we investigated relationships between 5-FU clearance and markers of DPD activity such as uracilemia (U), dihydrouracilemia (UH2)/U ratio, or genotype of the gene encoding DPD (DPYD). All patients with gastrointestinal cancers who received 5-FU-based regimens form March 2018 to June 2020 were included in our study. They routinely benefited of a pre-therapeutic DPYD genotyping and phenotyping. During 5-FU infusion, blood samples were collected to measure 5-FU steady-state concentration in order to adapt 5-FU doses at the following cycles. A total of 169 patients were included. Median age was 68 (40-8</pubmed_abstract><journal>Pharmaceuticals (Basel, Switzerland)</journal><pagination>E416</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7700344</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure.</pubmed_title><pmcid>PMC7700344</pmcid><pubmed_authors>Dolat M</pubmed_authors><pubmed_authors>Goirand F</pubmed_authors><pubmed_authors>Ghiringhelli F</pubmed_authors><pubmed_authors>Vincent J</pubmed_authors><pubmed_authors>Macaire P</pubmed_authors><pubmed_authors>Bengrine-Lefevre L</pubmed_authors><pubmed_authors>Royer B</pubmed_authors><pubmed_authors>Palmier R</pubmed_authors><pubmed_authors>Hennequin A</pubmed_authors><pubmed_authors>Schmitt A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure.</name><description>In order to limit 5-fluorouracil (5-FU) toxicity, some health agencies recommend evaluating dihydropyrimidine dehydrogenase (DPD) deficiency before any 5-FU treatment introduction. In our study, we investigated relationships between 5-FU clearance and markers of DPD activity such as uracilemia (U), dihydrouracilemia (UH2)/U ratio, or genotype of the gene encoding DPD (DPYD). All patients with gastrointestinal cancers who received 5-FU-based regimens form March 2018 to June 2020 were included in our study. They routinely benefited of a pre-therapeutic DPYD genotyping and phenotyping. During 5-FU infusion, blood samples were collected to measure 5-FU steady-state concentration in order to adapt 5-FU doses at the following cycles. A total of 169 patients were included. Median age was 68 (40-8</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Nov</publication><modification>2025-04-04T22:36:52.647Z</modification><creation>2021-02-20T03:07:30Z</creation></dates><accession>S-EPMC7700344</accession><cross_references><pubmed>33238487</pubmed><doi>10.3390/ph13110416</doi></cross_references></HashMap>